Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Insights, Forecast to 2034
Market Analysis and InsightsGlobal Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market
Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors key companies include Amgen, Mirati Therapeutics, Novartis, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation and Jacobio Pharmaceuticals, etc. Amgen, Mirati Therapeutics, Novartis are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the share will be % in 2029. Moreover, China, plays a key role in the whole Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market and estimated to attract more attentions from industry insiders and investors.
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors can be divided into Direct Inhibitors and Signal transduction inhibitors, etc. Direct Inhibitors is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2029.
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is widely used in various fields, such as Retail Pharmacy, Hospital Pharmacy and Online Pharmacy,, etc. Retail Pharmacy provides greatest supports to the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors industry development. In 2022, global % revenue of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors went into Retail Pharmacy filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Amgen
Mirati Therapeutics
Novartis
Genentech
Verastem Oncology
Revolution Medicines
Cardiff Oncology
Immuneering Corporation
Jacobio Pharmaceuticals
BridgeBio Pharma
Deciphera Pharmaceuticals
Elicio Therapeutics
InventisBio
Gritstone Bio
D3 Bio
Segment by Type
Direct Inhibitors
Signal transduction inhibitors
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors introduction, etc. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports’s Conclusions of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors key companies include Amgen, Mirati Therapeutics, Novartis, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation and Jacobio Pharmaceuticals, etc. Amgen, Mirati Therapeutics, Novartis are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the share will be % in 2029. Moreover, China, plays a key role in the whole Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market and estimated to attract more attentions from industry insiders and investors.
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors can be divided into Direct Inhibitors and Signal transduction inhibitors, etc. Direct Inhibitors is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2029.
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is widely used in various fields, such as Retail Pharmacy, Hospital Pharmacy and Online Pharmacy,, etc. Retail Pharmacy provides greatest supports to the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors industry development. In 2022, global % revenue of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors went into Retail Pharmacy filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Amgen
Mirati Therapeutics
Novartis
Genentech
Verastem Oncology
Revolution Medicines
Cardiff Oncology
Immuneering Corporation
Jacobio Pharmaceuticals
BridgeBio Pharma
Deciphera Pharmaceuticals
Elicio Therapeutics
InventisBio
Gritstone Bio
D3 Bio
Segment by Type
Direct Inhibitors
Signal transduction inhibitors
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors introduction, etc. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports’s Conclusions of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices